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ABSTRACT
Mechanisms underlying therapy resistance of tumor cells include protein kinase 
Akt. Putative Akt targets include store-operated Ca2+-entry (SOCE) accomplished by 
pore forming ion channel unit Orai1 and its regulator STIM1. We explored whether 
therapy resistant (A2780cis) differ from therapy sensitive (A2780) ovary carcinoma 
cells in Akt, Orai1, and STIM1 expression, Ca2+-signaling and cell survival following 
cisplatin (100µM) treatment. Transcript levels were quantified with RT-PCR, protein 
abundance with Western blotting, cytosolic Ca2+-activity ([Ca2+]i) with Fura-2-
fluorescence, SOCE from increase of [Ca2+]i following Ca2+-readdition after Ca2+-
store depletion, and apoptosis utilizing flow cytometry. Transcript levels of Orai1 
and STIM1, protein expression of Orai1, STIM1, and phosphorylated Akt, as well as 
SOCE were significantly higher in A2780cis than A2780 cells. SOCE was decreased 
by Akt inhibitor III (SH-6, 10µM) in A2780cis but not A2780 cells and decreased 
in both cell lines by Orai1 inhibitor 2-aminoethoxydiphenyl borate (2-ABP, 50µM). 
Phosphatidylserine exposure and late apoptosis following cisplatin treatment were 
significantly lower in A2780cis than A2780 cells, a difference virtually abolished by 
SH-6 or 2-ABP. In conclusion, Orai1/STIM1 expression and function are increased in 
therapy resistant ovary carcinoma cells, a property at least in part due to enhanced 
Akt activity and contributing to therapy resistance in those cells.
INTRODUCTION
Cytosolic Ca2+ activity participates in the regulation 
of a variety of fundamental cellular mechanisms including 
excitation, exocytosis, migration, cell proliferation and 
cell death [1-5]. Mechanisms contributing to the regulation 
of cytosolic Ca2+ concentration include Ca2+ release from 
intracellular stores and subsequent activation of store 
operated Ca2+ entry (SOCE) or Ca2+ release activated 
Ca2+ channel ICRAC, which are accomplished by the pore 
forming Ca2+ channel subunits Orai1, Orai2 and/or Orai3 
[6-10] as well as their regulators STIM1 and/or STIM2 
[11-15]. Orai1 and STIM1 are expressed in tumor cells 
and may well contribute to the survival of therapy resistant 
cells [16-20]. 
STIM1 and Orai1 upregulate SOCE via activation 
of Akt/mTOR in human pulmonary arterial smooth 
muscle cells [21]. In addition Orai1 and thus SOCE is up-
regulated in both mast cells [22] and platelets [23] by the 
serum & glucocorticoid inducible kinase SGK1, which 
counteracts Orai1 degradation by the ubiquitin ligase 
Nedd4-2 [22] and stimulates NF-κB dependent Orai1 
transcription [24]. SGK1 targets are in large part shared 
by PKB/Akt isoforms [25]. Thus, it is feasible that Orai1 
is similarly regulated by PKB/Akt isoforms.
The present study explored whether Orai1 and 
STIM1 are expressed in ovary carcinoma cells and 
whether their expression and function differs between 
therapy resistant and therapy sensitive ovary carcinoma 
cells. To this end, Orai1 and STIM1 transcript and protein 
expression, SOCE as well as apoptosis following cisplatin 
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treatment were determined in therapy resistant and therapy 
sensitive ovary carcinoma cells. 
RESULTS
RT-PCR was employed to explore whether ovary 
carcinoma cells transcribe Orai1 and/or STIM1 and 
whether the transcript levels are different between therapy 
sensitive A2780 and therapy resistant A2780cis ovary 
carcinoma cells. As illustrated in Fig.1, both cell lines 
express Orai1 and STIM1. The transcript levels were, 
however, significantly higher in therapy resistant A2780cis 
than in therapy sensitive A2780 ovary carcinoma cells. 
In line with the differences in Orai1 and STIM1 
transcript levels, Western blotting analysis revealed similar 
differences in protein abundance. Indeed, as illustrated 
in Fig. 2, the Orai1 and STIM1 protein expression was 
significantly higher in therapy resistant A2780cis than in 
therapy sensitive A2780 ovary carcinoma cells.
Fura-2-fluorescence was employed in order to test 
whether the differences in Orai1 and STIM1 transcript 
levels and protein abundance were paralleled by 
corresponding differences in store operated Ca2+ entry. 
The Fura-2-fluorescence ratio prior to extracellular Ca2+ 
removal was similar in therapy sensitive A2780 (0.298 ± 
0.003 a.u., n = 7) and therapy resistant A2780cis (0.309 
± 0.003 a.u., n = 7) ovary carcinoma cells. Addition of 
the store-depleting sarco-/endoplasmic reticulum Ca2+-
ATPase (SERCA) inhibitor thapsigargin (1 µM) triggered 
release of Ca2+ from intracellular stores, leading to rapid, 
transient increase in cytosolic Ca2+ activity. The increase 
of intracellular Ca2+ concentration following thapsigargin 
treatment was again similar in therapy sensitive A2780 
and therapy resistant A2780cis ovary carcinoma cells 
(Fig. 3). As illustrated in Fig. 3, the subsequent addition 
of extracellular Ca2+ was followed by a rapid increase 
of Fura-2-fluorescence in both cell types reflecting store 
operated Ca2+ entry (SOCE). Both, peak and slope of 
SOCE were significantly higher in therapy resistant 
A2780cis than in therapy sensitive A2780 ovary carcinoma 
cells. The Orai1 inhibitor 2-APB (50 µM) decreased the 
peak Ca2+ increase from 0.19 ± 0.02 arbitrary units (n = 
6) to 0.07 ± 0.01 arbitrary units (n = 5) in A2780 ovary 
carcinoma cells and from 0.49 ± 0.03 arbitrary units (n = 
6) to 0.04 ± 0.01 arbitrary units (n = 5) A2780cis ovary 
carcinoma cells (Fig. 4).
Additional experiments attempted to elucidate 
mechanisms accounting for the differences in Orai1 and 
STIM1 abundance as well as SOCE between therapy 
Fig. 1: Transcript levels of Orai1 and STIM1 in therapy 
sensitive and therapy resistant ovary carcinoma cells. 
Arithmetic means ± SEM (n = 9) of Orai1 (A) and STIM1 (B) 
transcript levels in therapy sensitive (white bars) and therapy 
resistant (black bars) ovary carcinoma cells. *** (p<0.001) 
indicates statistically significant difference from therapy 
sensitive ovary carcinoma cells (ANOVA). 
Fig. 2: Protein abundance of Orai1 and STIM1 in therapy sensitive and therapy resistant ovary carcinoma cells. A,B. Original 
Western blot of whole tissue lysate protein of Orai1 (A) and STIM1 (B) as well as GAPDH in therapy sensitive and therapy resistant 
ovary carcinoma cells. C,D. Arithmetic means ± SEM (n = 4) of the Orai1/GAPDH (C) and STIM1/GAPDH (D) protein abundance ratios 
in therapy sensitive (white bars) and therapy resistant (black bars) ovary carcinoma cells. *** (p<0.001) indicates statistically significant 
difference from therapy sensitive ovary carcinoma cells (ANOVA). 
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resistant A2780cis and therapy sensitive A2780 ovary 
carcinoma cells. A candidate kinase was Akt. Thus, 
Western blotting analysis was employed to test whether 
Akt and p-Akt are differentially expressed in therapy 
resistant A2780cis and in therapy sensitive A2780 ovary 
carcinoma cells. As a result, the protein abundance of 
p-Akt/Akt was indeed significantly higher in therapy 
resistant A2780cis than in therapy sensitive A2780 ovary 
carcinoma cells (Fig. 5). To further analyze whether 
Akt activity was required for the differences in SOCE, 
Fura-2-fluorescence experiments were performed in the 
absence and presence of Akt inhibitor III (SH-6) (Fig. 
4). Pretreatment with SH-6 (10 µM) did not significantly 
modify the Fura-2-fluorescence of therapy sensitive 
A2780 (0.35 ± 0.01 a.u., n = 6) and therapy resistant 
A2780cis (0.35 ± 0.01 a.u., n = 6) ovary carcinoma cells 
prior to triggering of SOCE. Moreover, the increase in 
cytosolic Ca2+ activity following addition of thapsigargin 
(1 µM) was in both cell types similar in the absence and 
presence of SH-6 (Fig. 4). However, the rapid increase 
of Fura-2-fluorescence following subsequent addition of 
extracellular Ca2+ was in therapy resistant A2780cis but 
not in therapy sensitive A2780 cells significantly blunted 
by SH-6 (Fig. 4). In the presence of SH-6 no statistically 
significant difference was observed in SOCE between 
therapy sensitive A2780 and therapy resistant A2780cis 
ovary carcinoma cells. 
In order to further explore the influence of Akt 
on SOCE, intracellular Ca2+ release and SOCE were 
determined in therapy sensitive ovary carcinoma cells 
transfected with constitutively active Akt or inactive 
Akt. As illustrated in Fig. 6, SOCE was significantly 
higher following transfection with constitutively active 
(T308DS473D) Akt than following transfection with 
inactive (T308AS473A) Akt. 
In order to test whether Akt sensitive regulation of 
Orai1 influenced the sensitivity of the ovary carcinoma 
cells to therapy, the effect of cisplatin on apoptosis of 
therapy sensitive A2780 and therapy resistant A2780cis 
cells was tested in the absence and presence of either Akt 
Fig. 3: Intracellular Ca2+ release and store operated Ca2+ 
entry (SOCE) in therapy sensitive and therapy resistant 
ovary carcinoma cells. A. Representative tracings of fura-2-
fluorescence-ratio in fluorescence spectrometry before, during 
and after Ca2+ depletion with subsequent addition of thapsigargin 
(1 µM) in therapy sensitive (white squares) and therapy resistant 
(black squares) ovary carcinoma cells. B,C. Arithmetic means (± 
SEM, n = 7, each experiment 10-30 cells) of slope (B) and peak 
(C) increase of fura-2-fluorescence-ratio following readdition of 
extracellular Ca2+ in therapy sensitive (white bars) and therapy 
resistant (black bars) ovary carcinoma cells. *** (p<0.001) 
indicates statistically significant difference from therapy 
sensitive ovary carcinoma cells (ANOVA).
Fig. 4. Effect of Akt inhibitor SH-6 and Orai1 
inhibitor 2-APB on intracellular Ca2+ release 
and store operated Ca2+ entry (SOCE) in therapy 
sensitive and therapy resistant ovary carcinoma 
cells. A,B. Representative tracings of fura-2-
fluorescence-ratio in fluorescence spectrometry during 
and after Ca2+ depletion with subsequent thapsigargin 
(1 µM) addition in therapy sensitive (A) and therapy 
resistant (B) ovary carcinoma cells without (white 
squares) and with presence of Akt inhibitor SH-6 (10 
µM, black squares) or Orai1 inhibitor 2-APB (50µM, 
gray squares). C,D. Arithmetic means (± SEM, n = 5-6, 
each experiment 10-30 cells) of slope (C) and peak 
(D) increase of fura-2-fluorescence-ratio following 
Ca2+ readdition in therapy sensitive (left bars) and 
therapy resistant (right bars) ovary carcinoma cells in 
the absence (white bars) and presence of Akt inhibitor 
SH-6 (10 µM, black bars) or Orai1 inhibitor 2-APB 
(50µM, gray bars). *** and ###(p<0.001) indicate 
statistically significant difference from absence of 
inhibitors (ANOVA).
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inhibitor SH-6 or Orai1 inhibitor 2-aminoethoxydiphenyl 
borate (2-APB). As illustrated in Fig. 7 and Fig. 8, 
A2780cis cells were resistant to apoptosis induced by 
cisplatin when compared with sensitive cells. Both SH-6 
(10 µM) and 2-ABP (50 µM) restored cisplatin sensitivity 
of resistant cells significantly to levels comparable with 
those observed in sensitive cells.
DISCUSSION
The present study disclosed the expression of 
Orai1 and STIM1 in both, therapy sensitive A2780 and 
therapy resistant A2780cis ovary carcinoma cells. More 
importantly, the present observations revealed that 
expression of both, Orai1 and STIM1, was significantly 
higher in therapy resistant A2780cis than in therapy 
sensitive A2780 ovary carcinoma cells. The increased 
expression of Orai1 and STIM1 was paralleled by 
corresponding differences in store operated Ca2+ entry 
(SOCE) in those cells. The enhanced Orai1/STIM1 
expression and activity was paralleled by enhanced p-Akt 
protein abundance and abrogated by the Akt inhibitor 
SH-6. Along those lines, transfection with active Akt 
was followed by increase of SOCE. Most importantly, 
pharmacological inhibition of either Akt or Orai1 
augmented cisplatin induced apoptosis of therapy resistant 
A2780cis ovary carcinoma cells and virtually abrogated 
the differences in cisplatin sensitivity between therapy 
sensitive A2780 and therapy resistant A2780cis ovary 
carcinoma cells.
The Ca2+ channel units Orai1, 2, or 3 [6-9] and their 
regulators STIM 1 or 2 [12, 13, 15] have been implicated 
in the resistance to apoptosis, in proliferation, and in 
migration of tumor cells [16-20, 26-34]. In cervical cancer 
cells STIM1 silencing abrogates proliferation and induces 
cell cycle arrest at the S and G2/M phase [32]. SOCE may 
trigger Ca2+ oscillations [35] which regulate a wide variety 
of cellular functions [36-40] including entering into the S 
and the M phase of the cell cycle [41, 42] and confering 
tumor cell survival [43, 44]. 
In contrast to oscillating cytosolic Ca2+ activity, 
a sustained increase of cytosolic Ca2+ activity leads 
to apoptosis [38, 40, 45-53]. Thus, survival of tumor 
Fig. 5: Protein abundance of Akt and p-Akt in therapy 
sensitive and therapy resistant ovary carcinoma cells. A. 
Original Western blot of whole tissue lysate protein of total Akt 
and phosphorylated p-Akt as well as GAPDH in therapy sensitive 
and therapy resistant ovary carcinoma cells. B. Arithmetic 
means ± SEM (n = 4) of the p-Akt/Akt protein abundance ratios 
in therapy sensitive (white bars) and therapy resistant (black 
bars) ovary carcinoma cells. *** (p<0.001) indicates statistically 
significant difference from therapy sensitive ovary carcinoma 
cells (ANOVA). 
Fig. 6: Intracellular Ca2+ release and store operated Ca2+ 
entry (SOCE) in therapy sensitive ovary carcinoma cells 
transfected with constitutively active Akt or inactive Akt. 
A. Representative tracings of fura-2 fluorescence-ratio in 
fluorescence spectrometry during and after Ca2+ depletion with 
subsequent thapsigargin (1 µM) addition in therapy sensitive 
ovary carcinoma cells transfected with constitutively active 
(T308DS473D) Akt (black squares) or inactive (T308AS473A) 
Akt (white squares). B,C. Arithmetic means (± SEM, n = 5, each 
experiment 10-30 cells) of slope (B) and peak (C) increase of 
fura-2-fluorescence-ratio in therapy sensitive ovary carcinoma 
cells transfected with constitutively active (T308DS473D) Akt 
(black bars) or inactive (T308AS473A) Akt (white bars). *** 
(p<0.001) indicates statistically significant difference from 
therapy sensitive ovary carcinoma cells (ANOVA).
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cells may depend on the delicate machinery underlying 
oscillating cytosolic Ca2+ activity.
 Ample evidence has previously been gathered on a 
role of Akt1 in stimulation of proliferation, inhibition of 
apoptosis and establishment of therapy resistance [54-62]. 
Interestingly, Akt1 phosphorylation has previously been 
shown to be suppressed by SOCE and to be up-regulated 
by inhibition of Orai1 expression [63]. Thus, the mutual 
regulation of Akt1 and Orai1 may be part of a negative 
feedback. 
Orai1/STIM1 is known to be up-regulated by the 
related serum & glucocorticoid inducible kinase [22, 
24]. Similar to Akt1, SGK1 is highly expressed in a wide 
variety of tumor cells [64-67]. SGK1 stimulates cell 
proliferation and confers cell survival [68-72] and thus 
actively participates in regulation of tumor growth [65, 73-
75]. However, we did not observe significant differences 
in SGK1 protein abundance between therapy sensitive 
A2780 and therapy resistant A2780cis ovary carcinoma 
cells (Suppl. Fig.1). Moreover, the specific SGK1 inhibitor 
EMD638683 [76] did not significantly affect SOCE 
in therapy resistant A2780cis ovary carcinoma cells 
and did not abrogate the differences in SOCE between 
therapy sensitive A2780 and therapy resistant A2780cis 
ovary carcinoma cells (Suppl. Fig.2). Thus, under the 
experimental conditions chosen, Akt1 rather than SGK1 
contributes to the therapy resistance of A2780cis ovary 
carcinoma cells.
The present observations reveal that Akt1 sensitive 
up-regulation of Orai1 contributes to or even accounts 
for cisplatin resistance of ovary carcinoma cells. The 
combined application of cisplatin with Akt1 inhibitors or 
Orai1 inhibitors may thus overcome therapy resistance 
of ovary carcinoma. Moreover, the same or similar 
Fig. 7: Effect of SOCE inhibitor 2-APB on cisplatin induced apoptosis of therapy sensitive and therapy resistant ovary carcinoma 
cells. A. Original dot plots of a representative experiment of annexin V binding plotted against propidium iodide staining of therapy 
sensitive cells (sensitive) and therapy resistant ovary carcinoma cells (resistant) without (left panels) and with (right panels) a 24 h exposure 
to 50 µM 2-APB and with (cisplatin) and without (control) cisplatin (100 µM, 24 h) treatment. The cells without loss of membrane integrity 
and externalized phosphatidylserine at the cell surface appear on the lower left quadrant of the dot plot. B. Arithmetic means (± SEM, n 
=5-6) of the percentage of therapy sensitive (sensitive) and therapy resistant (resistant) ovary carcinoma cells binding Annexin V following 
24 h exposure to DMSO (1‰, white bars) or 2-APB (50 µM, black bars) prior to (control) and following (cisplatin) treatment with cisplatin 
(100 µM, 24 h). *** (p<0.001) indicates statistically significant difference from respective value without 2-APB exposure, ### (p<0.001) 
indicates statistical difference from therapy sensitive cells following exposure to DMSO (ANOVA). C. Arithmetic means (± SEM, n =5-6) 
of the percentage of therapy sensitive (sensitive) and therapy resistant (resistant) ovary carcinoma cells undergoing late apoptosis following 
24 h exposure to DMSO (1‰, white bars) or 2-APB (50 µM, black bars) prior to (control) and following (cisplatin) treatment with cisplatin 
(100 µM, 24 h). * (p<0.05) indicates statistically significant difference from respective value without 2-APB exposure, # (p<0.05) indicates 
statistical difference from therapy sensitive cells following exposure to DMSO (ANOVA).
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mechanisms may be operative in other tumor cell types. 
Different Akt isoforms [77-79], SGK isoforms [65, 80], 
Orai/STIM isoforms [81-83] or other Ca2+ channels 
[84-89] may confer survival and thus establish therapy 
resistance of other tumor cell types. The combination of 
cytostatic therapy or radiation with the respective kinase 
or channel inhibitors may thus be a novel therapeutic 
approach to overcome therapy resistance of tumors. 
In conclusion, Orai1 is expressed in therapy 
sensitive A2780 and therapy resistant A2780cis ovary 
carcinoma cells. Orai1 transcript levels, Orai1 protein 
abundance and store operated Ca2+ entry are all higher 
in therapy resistant A2780cis than in therapy sensitive 
A2780 ovary carcinoma cells. The difference in SOCE 
between therapy resistant and therapy sensitive ovary 
carcinoma cells is paralleled by and at least partially due to 
upregulation of Orai1 by Akt. Akt dependent upregulation 
of SOCE contributes to or even accounts for the therapy 
resistance.
METHODS
Ethics Statement
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
Fig. 8: Effect of Akt inhibitor SH-6 on cisplatin induced apoptosis of therapy sensitive and therapy resistant ovary carcinoma 
cells. A. Original dot plots of annexin V binding plotted against propidium iodide in therapy sensitive cells (sensitive) and therapy resistant 
(resistant) ovary carcinoma cells without (left panels) and with (right panels) a 24 h exposure to 10 µM SH-6 and without (control) and 
with (cisplatin) treatment with cisplatin (100 µM, 24 h). The cells without loss of membrane integrity and externalized phosphatidylserine 
at the cell surface appear on the lower left quadrant of the dot plot. B. Arithmetic means (± SEM, n = 6) of the percentage of therapy 
sensitive (sensitive) and therapy resistant (resistant) ovary carcinoma cells binding Annexin V following 24 h exposure to DMSO (1‰, 
white bars) or SH-6 (10 µM, black bars) prior to (control) and following treatment with cisplatin (100 µM, 24 h) (cisplatin). *** (p<0.001) 
indicates statistically significant difference from respective value without SH-6 exposure, ### (p<0.001) indicates statistical difference from 
therapy sensitive cells following exposure to DMSO (ANOVA). C. Arithmetic means (± SEM, n = 6) of the percentage of therapy sensitive 
(sensitive) and therapy resistant (resistant) ovary carcinoma cells undergoing late apoptosis following 24 h exposure to DMSO (1‰, white 
bars) or SH-6 (10 µM, black bars) prior to (control) and following (cisplatin) treatment with cisplatin (100 µM, 24 h). ** (p<0.01) indicates 
statistically significant difference from respective value without SH-6 exposure, # (p<0.05) indicates statistical difference from therapy 
sensitive cells following exposure to DMSO (ANOVA).
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institutional review board.
Cell culture
Experiments were performed in cisplatin-resistant 
cells (A2780cis) and their therapy sensitive parent cell 
(A2780) (ECACC catalogue no. 93112519). A2780cis has 
been generated by exposure to increasing concentrations of 
cisplatin and is further resistant to melphalan, adriamycin 
and irradiation [90-92]. The cells were cultured in 
Dulbecco’s RPMI media, containing 10% fetal calf serum 
and 1% antibiotic/antimycotic solution.
Real-time PCR
Total RNA was extracted from ovary carcinoma 
cells in TriFast (Peqlab, Erlangen, Germany) according 
to the manufacturer’s instructions. After DNAse digestion 
reverse transcription of total RNA was performed using 
Transcriptor High Fidelity cDNA Synthesis Kit (Roche 
Diagnostics, Penzberg, Germany). Real-time polymerase 
chain reaction (RT-PCR) of the respective genes were set 
up in a total volume of 20 µl using 40 ng of cDNA, 500 
nM forward and reverse primer and 2x GoTaq® qPCR 
Master Mix (Promega,Hilden, Germany) according to 
the manufacturer’s protocol. Cycling conditions were as 
follows: initial denaturation at 95°C for 2 min, followed 
by 40 cycles of 95°C for 15 sec, 58°C for 15 sec and 68°C 
for 20 sec. For amplification the following primers were 
used (5`->3`orientation): 
for Orai1: 
fw: CGTATCTAGAATGCATCCGGAGCC
rev: CAGCCACTATGCCTAGGTCGACTAGC
for STIM1: 
fw: CCTCGGTACCATCCATGTTGTAGCA
rev: GCGAAAGCTTACGCTAAAATGGTGTCT 
for Tbp: 
fw: GCCCGAAACGCCGAATAT
rev: CCGTGGTTCGTGGCTCTCT
Specificity of PCR products was confirmed by 
analysis of a melting curve. Real-time PCR amplifications 
were performed on a CFX96 Real-Time System (Bio-Rad) 
and all experiments were done in duplicate. The house-
keeping gene Tbp (TATA binding protein) was amplified 
to standardize the amount of sample RNA. Relative 
quantification of gene expression was achieved using the 
ΔCT method as described earlier [93, 94].
Western blotting
For total protein analysis, cells were harvested 
with lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton 
X-100, 0.5% Na-deoxycholate, 0.4% β-Mercaptoethanol, 
Proteinase-Inhibitor Cocktail, Roche, Mannheim, 
Germany). Clarified protein lysate was applied to a 
polyacrylamide gel and analyzed by western blotting [95, 
96]. To this end, 30-50 µg protein of whole cell lysate 
was incubated with primary antibody for Orai1 (1:1000, 
Millipore, Bedford, MA, USA, [22]), STIM1 (1:1000, 
cell signaling, Danvers, MA, USA, [97]), Akt (1:1000, 
cell signaling, Danvers, MA, USA, [93], Phospho-Akt 
(Thr308) (1:1000, cell signaling, Danvers, MA, USA, [93]
and GAPDH (1:1000, cell signaling, Danvers, MA, USA, 
[98]). For detection secondary antibody conjugated with 
horseradish peroxidase (HRP) (1:2000, Cell Signaling, 
Danvers, MA, USA) was used. Antibody binding was 
identified with ECL detection reagent (Amersham, 
Freiburg, Germany). Bands were quantified with Quantity 
One Software (Biorad, München, Germany [22]). The 
appropriate band has been defined by using Orai1 
overexpressing cells [22, 24].
Ca2+ measurements
Fura-2 fluorescence was utilized to determine 
intracellular Ca2+ concentrations [97]. Cells were loaded 
with Fura-2/AM (2 µM, Invitrogen, Goettingen, Germany) 
for 20 min at 37°C. Cells were excited alternatively at 340 
nm and 380 nm through an objective (Fluor 40×/1.30 oil) 
built in an inverted phase-contrast microscope (Axiovert 
100, Zeiss, Oberkochen, Germany). Emitted fluorescence 
intensity was recorded at 505 nm. Data were acquired 
using specialized computer software (Metafluor, Universal 
Imaging, Downingtown, USA). Cytosolic Ca2+ activity 
was estimated from the 340 nm/380 nm ratio. SOCE was 
determined by extracellular Ca2+ removal and subsequent 
Ca2+ readdition in the presence of thapsigargin (1 µM, 
Invitrogen) [99]. For quantification of Ca2+ entry, the 
slope (delta ratio/s) and peak (delta ratio) were calculated 
following readdition of Ca2+.
 Experiments were performed with Ringer 
solution containing (in mM): 125 NaCl, 5 KCl, 1.2 
MgSO4, 2 CaCl2, 2 Na2HPO4, 32 HEPES, 5 glucose, pH 
7.4. To reach nominally Ca2+-free conditions, experiments 
were performed using Ca2+-free Ringer solution containing 
(in mM): 125 NaCl, 5 KCl, 1.2 MgSO4, 2 Na2HPO4, 32 
HEPES, 0.5 EGTA, 5 glucose, pH 7.4.
Determination of apoptosis 
To determine apoptosis, 105 cells/100μl in complete 
DMEM were incubated in 70% ethanol (molecular grade, 
Sigma) on ice for 30 minutes, centrifuged at 1600 RPM 
for 3 minutes at 4oC, added to 200μl of hypotonic buffer 
(0.1% sodium citrate, 0.1% triton X-100, 2mM CaCl2, 
20U/ml RNAse A in deionized water) together with 24μl/
ml Annexin V FITC (Mabtag, Germany) and 50 μg/ml 
propidium iodide (Mabtag, Germany) as well as incubated 
on ice in the dark for 60 minutes. The cells were washed 
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once at 1600 RPM for 3 minutes, resuspended in PBS-
1% BSA and measured immediately with an excitation 
wavelength of 488 nm and an emission wavelength of 
530 nm (FL-1) versus 585 nm (FL-2) with flow cytometry 
[100] utilizing a FACS Calibur (BD, Heidelberg, 
Germany).
Statistical ananlysis
Data are provided as means ± SEM; n represents 
the number of independent experiments. All data were 
tested for significance using Student’s unpaired two-
tailed t-test, one sample t-test or ANOVA (Dunnett’s test), 
where applicable. Results with p<0.05 were considered 
statistically significant.
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